News Conference News TCT 2023 Some Surprises in Low-Risk TAVI Follow-up: PARTNER 3 and Evolut Trials Michael O'Riordan October 24, 2023
News Conference News TCT 2022 Pre-AVR Cardiac Damage in PARTNER Patients Linked to Poorer QoL at 1 Year L.A. McKeown September 23, 2022
News Conference News TCT 2021 SURTAVI: Self-Expanding TAVI Valve Holds Up vs SAVR Through 5 Years Todd Neale November 05, 2021
News Conference News TCT 2019 Early Mortality Rates After TAVR Halved in a Decade, With Some Gender Differences L.A. McKeown October 09, 2019
News Conference News TCT 2019 Long-term PARTNER 2A Results Put Spotlight on Paravalvular Leak in TAVR Todd Neale September 29, 2019
Presentation TCT 2019 PARTNER 2A: 5-Year Outcomes From a Randomized Trial of Transcatheter vs. Surgical Aortic Valve Replacement in Intermediate-Risk Patients With Severe Aortic Stenosis Presenter: Vinod Thourani September 28, 2019
News Opinion Editor's Corner TCT 2019 TCT 2019 Day Three: Thowback Saturday Revisits COAPT, PARTNER 2A, and EXCEL Shelley Wood September 28, 2019
News Opinion Editor's Corner TCT 2019 TCT 2019 Day Two: Transcatheter Valves, New and Old Shelley Wood September 27, 2019
News Conference News TCT 2019 TCT 2019: Pharmacotherapy in PCI, Head-to-Head Valves, YouTube Rappers, and More Shelley Wood September 19, 2019
News Opinion Editor's Corner TCT 2017 My Takeaways From TCT 2017: Show Up, Keep It Civil, and Bring Your Best Self Shelley Wood November 22, 2017
News Conference News TCT 2017 A-fib Signals Worse Prognosis After Aortic Valve Replacement in Intermediate-Risk Patients Todd Neale November 08, 2017
Presentation TCT 2017 TCT 8391: Atrial Fibrillation Is Associated With Increased Mortality in Intermediate-Risk Patients Undergoing TAVR or SAVR - Insights From the PARTNER 2A and PARTNER 2 S3i Trials Presenter: Steven R. Bailey, Patrick W. Serruys, Angelo Biviano, MD November 01, 2017
News Conference News TCT 2017 Intermediate-Risk TAVR Substantially More Cost-effective Than Surgery Yael L. Maxwell October 31, 2017
Presentation TCT 2017 PARTNER 2A and SAPIEN 3 Cost-effectiveness: Cost-effectiveness of TAVR vs SAVR in Intermediate-Risk Patients With Aortic Stenosis Presenter: Patrick W. Serruys, David J. Cohen October 31, 2017
Presentation TCT 2017 Viewpoint #1: PARTNER 2A and SURTAVI are Convincing TAVR is Preferred in ALL (Appropriate) Intermediate-Risk Patients Presenter: Michael J. Reardon October 30, 2017
News Conference News TCT 2017 TCT 2017: High Hopes in Denver for Complex PCI, Shorter DAPT Durations, TAVR Costs, and More Shelley Wood October 20, 2017
News Opinion Editor's Corner TCT 2016 My Takeaways From TCT 2016: Surprises, Presuppositions, and the Gift of the Giveaway Shelley Wood November 07, 2016
News Conference News TCT 2016 Transfemoral—but Not Transthoracic—TAVR Has Early Quality-of-Life Advantage Over Surgery in Intermediate-Risk Patients Todd Neale November 02, 2016
Presentation TCT 2016 Intermediate-Risk Studies I: Synthesis of the PARTNER 2A and the Sapien 3 Intermediate-Risk Trials Presenter: Patrick T. O'Gara, Alec S. Vahanian, Susheel K. Kodali October 30, 2016